ALCAM and non-small cell lung carcinoma: In a recent study, Lim and his group identified a combination of CD166-positive and Lin-negative sub-population of lung cancer cells that link a glycine metabolism enzyme to tumour formation as a novel therapy targeting a specific metabolic pathway in NSCLC [136].